Effectiveness of BNT162b2 and ChAdOx1 Vaccines against Symptomatic COVID-19 among Healthcare Workers in Kuwait: A Retrospective Cohort Study.
Middle East
coronavirus disease
healthcare professionals
infectious diseases
public health
vaccine effectiveness
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
07 Dec 2021
07 Dec 2021
Historique:
received:
23
10
2021
revised:
28
11
2021
accepted:
03
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Estimating vaccine effectiveness (VE) against severe, acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers (HCWs) is necessary to demonstrate protection from the disease. Between 24 December 2020 and 15 June 2021, we determined the factors associated with vaccine coverage and estimated VE against SARS-CoV-2 infection in HCWs at a secondary hospital in Kuwait. We extracted sociodemographic, occupational, SARS-CoV-2 infection, and vaccination data for eligible HCWs from the hospital records. Vaccine coverage percentages were cross-tabulated with the HCW factors. Cox regression was used to estimate hazard ratios in vaccinated versus unvaccinated. 3246 HCWs were included in the analysis, of which 82.1% received at least one vaccine dose (50.4% only one dose of ChAdOx1, 3.3% only one dose of BNT162b2, and 28.3% two doses of BNT162b2). However, 17.9% of HCWs were unvaccinated. A significantly lower vaccination coverage was reported amongst female HCWs, younger age group (20-30 years), and administrative/executive staff. The adjusted VE of fully vaccinated HCWs was 94.5% (95% CI = 89.4-97.2%), while it was 75.4% (95% CI = 67.2-81.6%) and 91.4% (95% CI = 65.1-97.9%) in partially vaccinated for ChAdOx1 and BNT162b2, respectively. BNT162b2 and ChAdOx1 vaccines prevented most symptomatic infections in HCWs across age groups, nationalities, and occupations.
Sections du résumé
BACKGROUND
BACKGROUND
Estimating vaccine effectiveness (VE) against severe, acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers (HCWs) is necessary to demonstrate protection from the disease. Between 24 December 2020 and 15 June 2021, we determined the factors associated with vaccine coverage and estimated VE against SARS-CoV-2 infection in HCWs at a secondary hospital in Kuwait.
METHODS
METHODS
We extracted sociodemographic, occupational, SARS-CoV-2 infection, and vaccination data for eligible HCWs from the hospital records. Vaccine coverage percentages were cross-tabulated with the HCW factors. Cox regression was used to estimate hazard ratios in vaccinated versus unvaccinated.
RESULTS
RESULTS
3246 HCWs were included in the analysis, of which 82.1% received at least one vaccine dose (50.4% only one dose of ChAdOx1, 3.3% only one dose of BNT162b2, and 28.3% two doses of BNT162b2). However, 17.9% of HCWs were unvaccinated. A significantly lower vaccination coverage was reported amongst female HCWs, younger age group (20-30 years), and administrative/executive staff. The adjusted VE of fully vaccinated HCWs was 94.5% (95% CI = 89.4-97.2%), while it was 75.4% (95% CI = 67.2-81.6%) and 91.4% (95% CI = 65.1-97.9%) in partially vaccinated for ChAdOx1 and BNT162b2, respectively.
CONCLUSIONS
CONCLUSIONS
BNT162b2 and ChAdOx1 vaccines prevented most symptomatic infections in HCWs across age groups, nationalities, and occupations.
Identifiants
pubmed: 34946418
pii: healthcare9121692
doi: 10.3390/healthcare9121692
pmc: PMC8701668
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
Vaccine. 2021 Nov 26;39(48):7021-7027
pubmed: 34740473
Vaccines (Basel). 2021 Jun 17;9(6):
pubmed: 34204252
Vaccines (Basel). 2021 May 21;9(6):
pubmed: 34063863
J Infect Public Health. 2022 Jan;15(1):10-12
pubmed: 34856434
PLoS Med. 2021 Nov 5;18(11):e1003823
pubmed: 34739480
Lancet. 2021 Jan 9;397(10269):72-74
pubmed: 33306990
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet. 2021 Mar 6;397(10277):875-877
pubmed: 33610193
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Int J Infect Dis. 2021 Jul;108:116-118
pubmed: 33992763
PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
Ann Transl Med. 2018 Apr;6(7):121
pubmed: 29955581
Infect Control Hosp Epidemiol. 2021 Dec;42(12):1517-1519
pubmed: 34167610
Br J Gen Pract. 2021 Sep 24;:
pubmed: 34750106
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
Lancet Infect Dis. 2021 Nov;21(11):1539-1548
pubmed: 34174190
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222